223 related articles for article (PubMed ID: 21253716)
1. Pharmacodynamic and pharmacokinetic drug interactions reported to VigiBase, the WHO global individual case safety report database.
Strandell J; Wahlin S
Eur J Clin Pharmacol; 2011 Jun; 67(6):633-41. PubMed ID: 21253716
[TBL] [Abstract][Full Text] [Related]
2. Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports.
Fernandez S; Lenoir C; Samer C; Rollason V
Pharmacol Res Perspect; 2020 Oct; 8(5):e00647. PubMed ID: 32881416
[TBL] [Abstract][Full Text] [Related]
3. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.
Conte C; Rousseau V; Vert C; Montastruc F; Montastruc JL; Durrieu G; Olivier P
Fundam Clin Pharmacol; 2020 Aug; 34(4):518-520. PubMed ID: 32022302
[TBL] [Abstract][Full Text] [Related]
4. A Feasibility Study of Drug-Drug Interaction Signal Detection in Regular Pharmacovigilance.
Hult S; Sartori D; Bergvall T; Hedfors Vidlin S; Grundmark B; Ellenius J; Norén GN
Drug Saf; 2020 Aug; 43(8):775-785. PubMed ID: 32681439
[TBL] [Abstract][Full Text] [Related]
5. Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase.
Strandell J; Caster O; Bate A; Norén N; Edwards IR
Drug Saf; 2011 Mar; 34(3):253-66. PubMed ID: 21332249
[TBL] [Abstract][Full Text] [Related]
6. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
[TBL] [Abstract][Full Text] [Related]
8. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
[TBL] [Abstract][Full Text] [Related]
9. Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.
Kröger E; Mouls M; Wilchesky M; Berkers M; Carmichael PH; van Marum R; Souverein P; Egberts T; Laroche ML
Ann Pharmacother; 2015 Nov; 49(11):1197-206. PubMed ID: 26324356
[TBL] [Abstract][Full Text] [Related]
10. Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years.
Karrer JE; Giovannoni L; Kullak-Ublick GA; Weiler S
Swiss Med Wkly; 2019 Jun; 149():w20085. PubMed ID: 31256417
[TBL] [Abstract][Full Text] [Related]
11. Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase®.
Svendsen K; Wood M; Olsson E; Nordeng H
Eur J Clin Pharmacol; 2018 May; 74(5):627-636. PubMed ID: 29290074
[TBL] [Abstract][Full Text] [Related]
12. An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme.
Masuka JT; Khoza S
Pharmacol Res Perspect; 2020 Oct; 8(5):e00657. PubMed ID: 32930524
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
14. Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports.
Wakao R; Taavola H; Sandberg L; Iwasa E; Soejima S; Chandler R; Norén GN
Drug Saf; 2019 Dec; 42(12):1487-1498. PubMed ID: 31559542
[TBL] [Abstract][Full Text] [Related]
15. Profile of adverse drug reaction reports in South Africa: An analysis of VigiBase® for the year 2017.
Steyn H
S Afr Med J; 2023 Jun; 113(6):26-33. PubMed ID: 37278262
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal medical records as a complement to routine drug safety signal analysis.
Star K; Watson S; Sandberg L; Johansson J; Edwards IR
Pharmacoepidemiol Drug Saf; 2015 May; 24(5):486-94. PubMed ID: 25623045
[TBL] [Abstract][Full Text] [Related]
17. Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy.
Leone R; Magro L; Moretti U; Cutroneo P; Moschini M; Motola D; Tuccori M; Conforti A
Drug Saf; 2010 Aug; 33(8):667-75. PubMed ID: 20635825
[TBL] [Abstract][Full Text] [Related]
18. Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database.
Montastruc JL; Lafaurie M; de Canecaude C; Durrieu G; Sommet A; Montastruc F; Bagheri H
Br J Clin Pharmacol; 2021 Nov; 87(11):4334-4340. PubMed ID: 33837554
[TBL] [Abstract][Full Text] [Related]
19. Adverse drug reactions in Ghanaian children: review of reports from 2000 to 2012 in VigiBase.
Cliff-Eribo KO; Choonara I; Dodoo A; Darko DM; Sammons H
Expert Opin Drug Saf; 2015; 14(12):1827-33. PubMed ID: 26436964
[TBL] [Abstract][Full Text] [Related]
20. Suspected adverse reactions reported for blood, blood components, and blood products in VigiBase.
Samukange WT; Lu TA; Souverein PC; Gardarsdottir H; Mantel-Teeuwisse AK
Transfusion; 2023 May; 63(5):982-992. PubMed ID: 36994873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
